Bayer produces pharmaceuticals, crop science products, and consumer health remedies globally for patients and farmers.
A major pharma (likely Bayer per context) offered approximately $2B cash for Biorce. The founder rejected it because selling to one pharma would compromise the neutral infrastructure model needed to serve the entire industry and capture the $120B CRO market.